
Study finds new therapeutic targets for neurodegenerative disease
AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method… Read More
